New IPO Issue Of Novartis backed Viamet Pharmaceuticals

Viamet Pharmaceuticals Holdings, a biotech developing metal-binding protein therapeutics to treat fungal diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

The Durham, NC-based company was founded in 2004. It plans to list on the Nasdaq under the symbol VMET. Morgan Stanley, Goldman Sachs, Guggenheim Securities and Needham & Co. are the joint bookrunners on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.